ES2872076T3 - Derivado de 4,6-diamino-quinolina-3-carbonitrilo en forma de modulador de cáncer Osaka tiroides (Cot) para el tratamiento de la enfermedad inflamatoria - Google Patents

Derivado de 4,6-diamino-quinolina-3-carbonitrilo en forma de modulador de cáncer Osaka tiroides (Cot) para el tratamiento de la enfermedad inflamatoria Download PDF

Info

Publication number
ES2872076T3
ES2872076T3 ES18186568T ES18186568T ES2872076T3 ES 2872076 T3 ES2872076 T3 ES 2872076T3 ES 18186568 T ES18186568 T ES 18186568T ES 18186568 T ES18186568 T ES 18186568T ES 2872076 T3 ES2872076 T3 ES 2872076T3
Authority
ES
Spain
Prior art keywords
alkyl
heterocyclyl
heteroaryl
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18186568T
Other languages
English (en)
Spanish (es)
Inventor
Elizabeth Bacon
Gayatri Balan
Chien-Hung Chou
Christopher Clark
Jeromy Cottell
Musong Kim
Thorsten Kirschberg
John Link
Gary Phillips
Scott Schroeder
Neil Squires
Kirk Stevens
James Taylor
William Watkins
Nathan Wright
Sheila Zipfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2872076T3 publication Critical patent/ES2872076T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
ES18186568T 2015-07-06 2016-06-30 Derivado de 4,6-diamino-quinolina-3-carbonitrilo en forma de modulador de cáncer Osaka tiroides (Cot) para el tratamiento de la enfermedad inflamatoria Active ES2872076T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189158P 2015-07-06 2015-07-06
US201562269060P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
ES2872076T3 true ES2872076T3 (es) 2021-11-02

Family

ID=56411943

Family Applications (3)

Application Number Title Priority Date Filing Date
ES21162393T Active ES3034100T3 (en) 2015-07-06 2016-06-30 4,6-diamino-quinoline-3-carbonitrile derivatives as cancer osaka thyroid (cot) modulators for treating crohn's disease and ulcerative colitis
ES18186568T Active ES2872076T3 (es) 2015-07-06 2016-06-30 Derivado de 4,6-diamino-quinolina-3-carbonitrilo en forma de modulador de cáncer Osaka tiroides (Cot) para el tratamiento de la enfermedad inflamatoria
ES16738976T Active ES2734713T3 (es) 2015-07-06 2016-06-30 Moduladores Cot y métodos de utilización de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES21162393T Active ES3034100T3 (en) 2015-07-06 2016-06-30 4,6-diamino-quinoline-3-carbonitrile derivatives as cancer osaka thyroid (cot) modulators for treating crohn's disease and ulcerative colitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16738976T Active ES2734713T3 (es) 2015-07-06 2016-06-30 Moduladores Cot y métodos de utilización de los mismos

Country Status (41)

Country Link
US (8) US20170008905A1 (OSRAM)
EP (4) EP3456717B1 (OSRAM)
JP (6) JP6430060B2 (OSRAM)
KR (5) KR20220129667A (OSRAM)
CN (4) CN114380799B (OSRAM)
AU (5) AU2016290820B2 (OSRAM)
BR (1) BR102016015656B1 (OSRAM)
CA (1) CA2971640C (OSRAM)
CL (1) CL2017003356A1 (OSRAM)
CO (1) CO2017013351A2 (OSRAM)
CR (1) CR20170599A (OSRAM)
CU (1) CU20170172A7 (OSRAM)
CY (1) CY1121750T1 (OSRAM)
DK (1) DK3191470T3 (OSRAM)
DO (1) DOP2017000311A (OSRAM)
EA (1) EA036788B1 (OSRAM)
EC (1) ECSP17084635A (OSRAM)
ES (3) ES3034100T3 (OSRAM)
HR (1) HRP20190853T1 (OSRAM)
HU (1) HUE043310T2 (OSRAM)
IL (4) IL274568B (OSRAM)
LT (1) LT3191470T (OSRAM)
MA (1) MA39422B1 (OSRAM)
ME (1) ME03425B (OSRAM)
MX (1) MX370984B (OSRAM)
MY (1) MY196173A (OSRAM)
NZ (2) NZ738525A (OSRAM)
PE (1) PE20180462A1 (OSRAM)
PH (2) PH12018500031A1 (OSRAM)
PL (3) PL3456717T3 (OSRAM)
PT (3) PT3896064T (OSRAM)
RS (1) RS58639B1 (OSRAM)
SA (1) SA517381350B1 (OSRAM)
SG (1) SG11201702041PA (OSRAM)
SI (3) SI3191470T1 (OSRAM)
SM (1) SMT201900244T1 (OSRAM)
SV (1) SV2017005605A (OSRAM)
TW (3) TWI699361B (OSRAM)
UA (1) UA123010C2 (OSRAM)
UY (1) UY36771A (OSRAM)
WO (1) WO2017007689A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
AU2016289817B2 (en) 2015-07-06 2019-01-31 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitrils as Cot modulators
EP3456717B1 (en) * 2015-07-06 2021-03-17 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
ES2800339T3 (es) 2016-06-30 2020-12-29 Gilead Sciences Inc 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
PL3597646T3 (pl) 2016-08-19 2023-12-11 Gilead Sciences, Inc. Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
WO2019065516A1 (ja) * 2017-09-26 2019-04-04 日本曹達株式会社 キノリン化合物および農園芸用殺菌剤
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) * 2018-03-23 2021-09-24 中国农业大学 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) * 2018-06-25 2018-10-16 中国药科大学 一种氘代Fiduxosin的制备方法
CN120053446A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
TW202235416A (zh) * 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
WO2021028323A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
KR102832308B1 (ko) 2019-08-15 2025-07-10 이도르시아 파마슈티컬스 리미티드 2-히드록시시클로알칸-1-카르바모일 유도체
MY207787A (en) 2019-08-29 2025-03-19 Idorsia Pharmaceuticals Ltd Alpha-d-galactopyranoside derivatives
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
JP2023520650A (ja) * 2020-03-30 2023-05-18 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
EP4613745A3 (en) * 2020-04-02 2025-11-26 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
CA3197095A1 (en) 2020-11-02 2022-05-05 Martin Bolli Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh) 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物
CN116888113A (zh) 2021-03-03 2023-10-13 爱杜西亚药品有限公司 经三唑基-甲基取代的α-D-吡喃半乳糖苷衍生物
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
KR20240019340A (ko) * 2021-06-11 2024-02-14 뉴로내슨트, 아이엔씨. 헤테로시클릭 유형의 친유성 소분자 치료의 지질 제제를 위한 방법 및 조성물
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2024245157A1 (zh) * 2023-05-30 2024-12-05 浙江星浩澎博医药有限公司 氮杂喹啉环衍生物
WO2024249983A1 (en) * 2023-06-02 2024-12-05 Westol, Llc 2,8-dihydroxyquinoline glucuronide derivatives with enhanced properties for use as anticancer, antiviral, antimicrobial, and other therapeutic applications
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
KR102732584B1 (ko) 2024-03-28 2024-11-21 (주)신한티이씨 전기 배전반의 화재 위험 감지 및 진압용 소화 장치

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4151298A (en) 1977-01-10 1979-04-24 Ciba-Geigy Corporation Anthelmintic compositions
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
KR20010022781A (ko) 1997-08-28 2001-03-26 도쿠시마 히데이치 시아노아크릴레이트 화합물을 함유하는 공업용 항균·항진균제, 살조제(殺藻劑) 및 생물 부착 방지제
ES2257864T3 (es) 1998-07-10 2006-08-01 Massachusetts Institute Of Technology Ligandos para metales y procesos mejorados catalizados por metales basados en los mismos.
CN1144786C (zh) * 1998-09-29 2004-04-07 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
JP4359150B2 (ja) 2002-03-20 2009-11-04 ブリストル−マイヤーズ スクイブ カンパニー フルオロオキシインドールのホスフェートプロドラッグ
DE602004010791T2 (de) 2003-03-03 2008-12-04 F. Hoffmann-La Roche Ag 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
WO2005019201A2 (en) 2003-08-19 2005-03-03 Wyeth Holdings Corporation Process for the preparation of 4-amino-3-quinolinecarbonitriles
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006247315A1 (en) * 2005-05-18 2006-11-23 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same
JP2008540656A (ja) * 2005-05-18 2008-11-20 ワイス Ｔｐｌ２キナーゼの３−シアノキノリン阻害物質ならびにそれを製造および使用する方法
US8232309B2 (en) 2005-10-28 2012-07-31 Abbott Laboratories Prodrugs of compounds that inhibit TRPV1 receptor
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
WO2008055950A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8389544B2 (en) 2007-01-17 2013-03-05 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
JP5985401B2 (ja) 2010-03-09 2016-09-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法
WO2011153942A1 (zh) 2010-06-09 2011-12-15 天津和美生物技术有限公司 氰基喹啉衍生物
WO2012153796A1 (ja) 2011-05-10 2012-11-15 協和発酵キリン株式会社 ピリミドジアゼピノン化合物
CN103957711A (zh) 2011-07-04 2014-07-30 拜耳知识产权有限责任公司 取代的异喹啉酮、异喹啉二酮、异喹啉三酮和二氢异喹啉酮或其各自的盐作为活性剂对抗植物非生物胁迫的用途
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2772482B1 (en) 2011-10-27 2016-03-09 Taisho Pharmaceutical Co., Ltd. Azole derivative
PL2776038T3 (pl) 2011-11-11 2018-06-29 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
JP6542794B2 (ja) 2013-12-12 2019-07-10 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー 二環式アルキル化合物、および合成
JP6741343B2 (ja) 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
WO2016007966A2 (en) * 2014-07-11 2016-01-14 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
CN106999451B (zh) 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
US10238636B2 (en) 2014-09-24 2019-03-26 Gilead Sciences, Inc. Methods of treating liver disease
BR112017013382A2 (pt) 2014-12-23 2018-02-14 Gilead Sciences Inc método para preparar um composto, composto, e, ácido.
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
HK1246232A1 (zh) 2015-01-09 2018-09-07 Gilead Apollo, Llc 用於治疗非酒精性脂肪肝病的acc抑制剂组合治疗
KR20170102352A (ko) 2015-01-16 2017-09-08 쓰리엠 이노베이티브 프로퍼티즈 컴파니 그리드 결과를 개선하기 위해 그리드 액션을 선택하기 위한 시스템 및 방법
EP3456717B1 (en) 2015-07-06 2021-03-17 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
AU2016289817B2 (en) * 2015-07-06 2019-01-31 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitrils as Cot modulators
PL3398598T3 (pl) 2015-12-31 2022-08-22 Hitgen Inc. Pochodne sulfonoamidowe oraz sposoby ich wytwarzania i zastosowanie
MX2018010427A (es) 2016-03-02 2019-03-06 Gilead Apollo Llc Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
US10702503B2 (en) 2016-06-21 2020-07-07 Phc Holdings Corporation Catalase inhibitor and method for measuring analyte using catalase inhibitor
ES2800339T3 (es) 2016-06-30 2020-12-29 Gilead Sciences Inc 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
PL3589636T3 (pl) 2017-03-03 2024-02-19 Gilead Sciences, Inc. Sposoby wytwarzania inhibitorów acc i ich form stałych
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
US20180333401A1 (en) 2017-04-12 2018-11-22 Gilead Sciences, Inc. Methods of treating liver disease
AU2018345817B2 (en) 2017-10-06 2021-10-28 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
US20220143153A1 (en) 2019-03-08 2022-05-12 The Regents Of The University Of California Compositions and methods for treating acne
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
JP2023520650A (ja) 2020-03-30 2023-05-18 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
EP4613745A3 (en) 2020-04-02 2025-11-26 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法

Also Published As

Publication number Publication date
CN119143730A (zh) 2024-12-17
JP6781221B2 (ja) 2020-11-04
AU2016290820B2 (en) 2019-03-07
JP6906021B2 (ja) 2021-07-21
NZ738525A (en) 2019-03-29
PT3191470T (pt) 2019-06-05
US20170008905A1 (en) 2017-01-12
CO2017013351A2 (es) 2018-05-21
MX2017004737A (es) 2017-06-19
MA39422B1 (fr) 2019-03-29
EP3456717B1 (en) 2021-03-17
US20230002407A1 (en) 2023-01-05
US11905299B2 (en) 2024-02-20
LT3191470T (lt) 2019-05-10
CN107922390A (zh) 2018-04-17
AU2022204050A1 (en) 2022-06-30
IL266995A (en) 2019-07-31
CU20170172A7 (es) 2018-06-05
KR20180022982A (ko) 2018-03-06
DK3191470T3 (en) 2019-04-15
AU2019203122B2 (en) 2020-10-01
US20200123172A1 (en) 2020-04-23
PT3456717T (pt) 2021-05-26
EA201792613A1 (ru) 2018-06-29
US9878995B2 (en) 2018-01-30
EP3456717A1 (en) 2019-03-20
CN109879859A (zh) 2019-06-14
JP2018193405A (ja) 2018-12-06
TWI748539B (zh) 2021-12-01
EP3191470A1 (en) 2017-07-19
KR102073641B1 (ko) 2020-02-05
TW202114673A (zh) 2021-04-16
MY196173A (en) 2023-03-17
CN114380799B (zh) 2024-10-01
JP2024100865A (ja) 2024-07-26
EP3896064B1 (en) 2025-05-21
JP6430060B2 (ja) 2018-11-28
JP2022082816A (ja) 2022-06-02
CR20170599A (es) 2018-02-28
MA39422A (fr) 2017-07-19
PL3896064T3 (pl) 2025-09-08
CN109879859B (zh) 2022-01-25
HRP20190853T1 (hr) 2019-06-28
JP2018520161A (ja) 2018-07-26
IL293770B1 (en) 2023-03-01
JP7138155B2 (ja) 2022-09-15
SI3896064T1 (sl) 2025-07-31
JP2019178178A (ja) 2019-10-17
PH12018500031B1 (en) 2018-07-09
SMT201900244T1 (it) 2019-05-10
IL293770B2 (en) 2023-07-01
EP3191470B1 (en) 2019-02-27
CA2971640C (en) 2020-09-22
UY36771A (es) 2017-01-31
KR20220129667A (ko) 2022-09-23
EP4613332A3 (en) 2025-12-10
IL256433B (en) 2019-06-30
NZ750707A (en) 2023-09-29
PL3456717T3 (pl) 2021-10-25
DOP2017000311A (es) 2018-01-15
US20170152240A1 (en) 2017-06-01
AU2022204050B2 (en) 2024-04-18
IL274568B (en) 2022-07-01
CY1121750T1 (el) 2020-07-31
US20180237455A1 (en) 2018-08-23
AU2019203122A1 (en) 2019-05-30
IL256433A (en) 2018-02-28
IL293770A (en) 2022-08-01
CN114380799A (zh) 2022-04-22
UA123010C2 (uk) 2021-02-03
KR101974793B1 (ko) 2019-05-02
PT3896064T (pt) 2025-07-03
IL266995B (en) 2020-05-31
EP4613332A2 (en) 2025-09-10
KR20240008398A (ko) 2024-01-18
CN107922390B (zh) 2019-05-10
ME03425B (me) 2020-01-20
AU2020257055A1 (en) 2020-11-12
US20250346609A1 (en) 2025-11-13
PH12018500031A1 (en) 2018-07-09
TW201712005A (zh) 2017-04-01
ECSP17084635A (es) 2018-01-31
CA2971640A1 (en) 2017-01-12
SI3191470T1 (sl) 2019-04-30
TWI634112B (zh) 2018-09-01
AU2020257055B2 (en) 2022-03-31
TW201908305A (zh) 2019-03-01
HUE043310T2 (hu) 2019-08-28
AU2016290820A1 (en) 2018-01-18
EA036788B1 (ru) 2020-12-21
PE20180462A1 (es) 2018-03-06
RS58639B1 (sr) 2019-05-31
ES2734713T3 (es) 2019-12-11
TWI699361B (zh) 2020-07-21
KR102443575B1 (ko) 2022-09-16
CL2017003356A1 (es) 2018-07-06
US11066414B2 (en) 2021-07-20
EP3896064A1 (en) 2021-10-20
IL274568A (en) 2020-06-30
JP2021042252A (ja) 2021-03-18
BR102016015656B1 (pt) 2021-11-03
WO2017007689A1 (en) 2017-01-12
KR20190045416A (ko) 2019-05-02
KR20200013120A (ko) 2020-02-05
US20240254137A1 (en) 2024-08-01
PH12020551397A1 (en) 2021-08-16
MX370984B (es) 2020-01-09
AU2024204902A1 (en) 2024-08-01
SA517381350B1 (ar) 2021-03-11
SG11201702041PA (en) 2017-04-27
BR102016015656A2 (pt) 2020-09-24
SI3456717T1 (sl) 2021-08-31
SV2017005605A (es) 2018-07-18
US20190248807A1 (en) 2019-08-15
PL3191470T3 (pl) 2019-08-30
ES3034100T3 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
ES2872076T3 (es) Derivado de 4,6-diamino-quinolina-3-carbonitrilo en forma de modulador de cáncer Osaka tiroides (Cot) para el tratamiento de la enfermedad inflamatoria
ES2800339T3 (es) 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
ES2849953T3 (es) 6-amino-quinolina-3-carbonitrilos como moduladores de cot
HK40059922A (en) 4,6-diamino-quinoline-3-carbonitrile derivatives as cancer osaka thyroid (cot) modulators for treating crohn's disease and ulcerative colitis
HK40005586B (en) 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
HK40005586A (en) 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
HK40071620B (zh) Cot调节剂及其使用方法
HK1240938B (en) Cot modulators and methods of use thereof
HK1240938A1 (en) Cot modulators and methods of use thereof
HK40008224A (en) 4,6-diaminoquinazolines as cot modulators and methods of use thereof
HK40008224B (en) 4,6-diaminoquinazolines as cot modulators and methods of use thereof